Every 10-Q that Barinthus Biotherapeutics plc American (BRNS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow BRNS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BRNS filings page.
Barinthus Biotherapeutics plc, a clinical-stage I&I-focused biopharma, reported a Q2 2026 net loss of $10.6 million and a six‑month net loss of $16.1 million, both lower than the prior-year periods as research and development and general and administrative expenses declined. Research and development spending for the first half fell to $7.5 million, reflecting the wind-down of infectious disease and oncology programs and increased focus on lead celiac candidate VTP‑1000, now in a Phase 1 AVALON trial. General and administrative expenses dropped to $9.6 million, helped by lower foreign-exchange impacts and depreciation after U.K. asset sales. Cash, cash equivalents and restricted cash totaled $59.6 million at June 30, 2026, and management expects this to fund standalone operations for at least 12 months.
The company is progressing a planned all-stock combination with Clywedog Therapeutics via a U.K. Scheme of Arrangement and parallel U.S. merger, under which each Barinthus ordinary share will convert into 0.1–0.166667 Topco common shares, subject to closing conditions. Topco may also conduct a self‑tender offer to repurchase up to $27.0 million of its stock. Barinthus received a Nasdaq extension until December 28, 2026 to regain minimum bid compliance and transferred its ADS listing to the Nasdaq Capital Market. The company continues to exit non-core programs, including repaying $1.0 million under its CEPI funding agreement for VTP‑500.
Barinthus Biotherapeutics plc reported sharply improved results for the three months ended March 31, 2026 while advancing its planned all‑stock merger with Clywedog Therapeutics. Net loss attributable to shareholders was $5.5 million, compared with $19.6 million a year earlier, driven mainly by lower operating expenses.
Research and development spending fell to $3.6 million from $8.3 million, reflecting the strategic shift toward autoimmune and inflammatory diseases and wind‑down of legacy infectious disease and oncology programs, while continuing the Phase 1 AVALON trial of lead celiac candidate VTP‑1000. General and administrative costs dropped to $2.5 million from $12.6 million, aided by foreign exchange gains and prior cost actions.
Cash, cash equivalents and restricted cash totaled $67.2 million as of March 31, 2026, with management expecting this to fund standalone operations for at least 12 months. The Clywedog merger structure includes a U.K. court‑sanctioned scheme of arrangement, creation of new parent Topco, potential self‑tender of up to $27.0 million of Topco common stock, and exchange ratios that will be finalized before closing.
Barinthus Biotherapeutics (BRNS) filed its Q3 2025 10‑Q, reporting a wider quarterly loss as it pivots to immunology and prepares for a planned combination with Clywedog. Net loss was $14.6 million for the quarter and $55.4 million year‑to‑date, driven by lower R&D and a one‑time non‑cash intangible impairment.
Cash and cash equivalents were $74.3 million (plus $1.4 million restricted) as of September 30, 2025, with operating cash outflow of $43.7 million for the nine months. R&D expense fell to $5.4 million in Q3 on program deprioritizations, while G&A was $5.2 million. The company recorded a $4.7 million impairment of acquired technology after announcing the Clywedog transaction. There was no license revenue in 2025 versus $15.0 million in the prior‑year period.
Barinthus agreed to a merger under which each ordinary share will convert into one share of Topco common stock, subject to court and shareholder approvals. Topco may elect a self‑tender of up to $27.0 million in its shares before merging Clywedog, whose stock will convert into 4.358932 Topco shares per share. The lead celiac candidate VTP‑1000 continues in Phase 1, with initial SAD data expected before the end of 2025.
Q2-25 snapshot: Barinthus Biotherapeutics (BRNS) posted a net loss of $21.1 million (-24.6 % YoY) or -$0.52/sh; six-month loss widened to $40.8 million. Cash & equivalents fell to $86.3 million from $110.7 million at FY-24, but management still forecasts liquidity into early-2027.
Expense trends: R&D dropped 32 % YoY to $8.0 million as infectious-disease and oncology projects were shelved; however, G&A more than doubled to $15.4 million due mainly to an $8.0 million foreign-exchange loss and restructuring costs, lifting total operating spend 24 % to $23.3 million.
Balance sheet & risk: Current assets declined 20 % to $100.4 million; equity slid to $102.5 million. There is no debt, but cash burn averaged ~$17 million per quarter, and accumulated deficit reached $278.4 million.
Pipeline focus: Strategy now centres on immunology & inflammation. Lead SNAP-TI asset VTP-1000 (celiac disease) has completed dosing of two single-ascending-dose cohorts; topline safety/biomarker data expected early Q4-25. VTP-300 (HBV) will finish current Phase 2 trials while partnering options are explored; CEPI-funded MERS vaccine program is being exited.
Key watch-points: 1) VTP-1000 Phase 1 read-out, 2) ability to rein in G&A, 3) partnership progress for VTP-300, and 4) sustaining cash runway under current burn.